[A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].
A 46-year-old woman underwent breast-conserving surgery. The patient was treated with six cycles of CMF and, subsequently, combination therapy with UFT and CPA. However, multiple metastases were detected in the thoracic vertebrae after two years and two months of surgery. Weekly administration of paclitaxel was initiated, but the drug could not be continued due to pancytopenia. CPT-11 (40 mg/body) once a week and medroxyprogesterone acetate (MPA) 600 mg a day was substituted for paclitaxel. During the treatment with CPT-11, no severe adverse reactions, such as myelosuppression and diarrhea, were observed, and the patient's condition was stable without discontinuing the chemotherapy. The results suggest that the low-dose CPT-11 and MPA therapy should improve the prognosis of advanced and recurrent breast cancers with only slight adverse effects.
Inoue
Mitsuhiro
M
Dept of Surgery, Hitoyoshi General Hospital.
Kimura
Masami
M
Horino
Kei
K
Nishimura
Takumasa
T
Kuhara
Hiroshi
H
Nakano
Masahiro
M
Kaneda
Hiroshi
H
Kume
Shuichi
S
Arima
Toshiharu
T
Uemura
Kuninori
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077146:Irinotecan; D015412:Mastectomy, Segmental; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D010198:Pancytopenia / Q000209:etiology*; D011788:Quality of Life
D000077146:Irinotecan; D017258:Medroxyprogesterone Acetate; D002166:Camptothecin